Just Out by our Partners at SWOG Cancer Research Network

Quantitative changes in tumor measurement according to RECISTv1.1 exhibit a linear correlation with PFS and OS up to a 4⃣0⃣% to 5⃣0⃣% increase in tumor size in patients with rare cancers undergoing combo immune checkpoint blockade in SWOG Cancer Research Network

⚡️ On Nature Medicine - A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma

#KidneyCancer #Immunotherapy OncoAlert OncLive.com

nature.com/articles/s4159…

Gran preceptorship de Cáncer de Vejiga experiencias compartidas con amigos de LATAM y Enrique Grande #MDAndersoncancercenter #Madrid #cancerdevejiga #secuenciancia #SIvsNO Urooncologia.arg Ethel Etchelet

⚡️ Investigating cabozantinib with or without PD-1/L1 inhibitors for metastatic clear cell renal cell carcinoma after prior immunotherapy.
Results show similar time to next therapy and overall survival for both regimens, aligning with phase 3 CONTACT-03 trial results.

⭕️1er día de análisis de evidencia 📈 con Enrique Grande LATAM #MDAndersoncancercenter #Madrid #cancerdevejiga #secuenciancia #SIvsNO RobertVC Gilberto Lopez Rosas Nicolás Mainardi Enrique Grande Juan Pablo Márquez Lara Emi Menna Urooncologia.arg

🔵Our group has been working on localized prostate cancer imaging for more than one and a half decades.
🔬🩻We began by optimizing MRI vs. pathology correlation using patient-specific molds.
🔷Over the years, we've developed organ segmentation and lesion detection models in

Martín Angel Rodrigo Sanchez Roger 🤝👍

The long and winding road to biomarkers for immunotherapy🏔️

A comprehensive analysis led by Laurence Buisseret of samples from pts with TNBC treated with pembrolizumab highlights the huge heterogeneity among TNBCs

Now out in ESMO Open ⬇️

OncoAlert

authors.elsevier.com/sd/article/S20…

RADIOSA trial:
🔸oligorecurrent PCa SBRT vs SBRT + 6 mo ADT
🔸 ADT improved bRFS and cRFS
🔸 more polymetastatic recurrences in the ADT arm.
🔹would love to see eugonad-relapse free survival.
🔹 will be interesting to see QoL data and compare with the DART trial
#ESTRO24

Great slide highlighting the contribution of common SNPs and rare genetic variants for #prostatecancer risk Yaw Nyame Heather H. Cheng #AUA24

💫🌟 🆕️Recent study on muscle-invasive bladder cancer compares trimodal therapy (TMT) and radical cystectomy (RC):
OncoAlert  Francesco Ditonno Alessandro Antonelli Simone Crivellaro Alexander Kutikov MD
GU Cast | Urology podcast!

🔄 No significant differences found in overall survival (OS) between TMT and RC,

Very well deserved! Tom Powles has done so much for the field of oncology also before this great success and surely he will do even more in the future! An amazing oncologist!

Auspicio institucional de la
Asociación Argentina de Oncología Clínica

Harold Somerville

Advances in #PrecisionMedicine rapidly transforming treatment options for #BladderCancer patients. Daniel Castellano Hospital Universitario 12 de Octubre discusses the importance of multidisciplinary approaches in patient care and research > bit.ly/3SvJ7yD

👉 Teragnosis: un mundo que se abre.
Agradecemos a Juan Pablo Sade y a Rodrigo Sanchez Roger por el enorme trabajo que realizaron estos días con tanta dedicación y generosidad🤗
🇦🇷UrooncoArgentina #APCCC24 OncoAlert Advanced Prostate Cancer Consensus Conference GU Cast | Urology podcast! EAU Edu Platform UROONCO
Neeraj Agarwal, MD, FASCO Asociación Argentina de Oncología Clínica (AAOC) UroTarget

👉Tumores anaplásicos.
Gran resumen de Juan Pablo Sade 👏👏👏
🇦🇷UrooncoArgentina #APCCC24 OncoAlert Advanced Prostate Cancer Consensus Conference GU Cast | Urology podcast! Rodrigo Sanchez Roger EAU Edu Platform UROONCO
Neeraj Agarwal, MD, FASCO Asociación Argentina de Oncología Clínica (AAOC) UroTarget

👉Inhibidores de PARP
Juan Pablo Sade nos cuenta todo sobre el tercer día en #APCCC24

🇦🇷UrooncoArgentina OncoAlert Advanced Prostate Cancer Consensus Conference GU Cast | Urology podcast! Rodrigo Sanchez Roger EAU Edu Platform UROONCO
Neeraj Agarwal, MD, FASCO Asociación Argentina de Oncología Clínica (AAOC) UroTarget

What is the diagnosis?

Dealing with inequality – what can we learn from the Brazilian Unified Healthcare System. Presented by Fernando Maluf, MD, PhD, Hospital Israelita Albert Einstein. #APCCC24 Written coverage by Zach Klaassen Georgia Cancer Center MCG Urology. > bit.ly/44kQkpF Advanced Prostate Cancer Consensus Conference

A ti Rodrigo Sanchez Roger y a todos nuestros colegas de LATAM, fue todo un placer conocerlos en #APCCC24 y espero que juntos tengamos la misma presencia en #ASCO24 !

Un fuerte abrazo a nuestros amigos de Argentina 🇦🇷y de toda Latinoamérica 🌎
TODOS SOMOS OncoAlert 🚨